Castle Biosciences COO Kristen Oelschlager Sells Shares
Kristen Oelschlager sold 8,587 shares of Castle Biosciences in a planned transaction.
Key Points
- Kristen Oelschlager, COO of Castle Biosciences, sold 8,587 shares at $20.71 each, totaling $177,837, on June 16, 2026.
- Castle Biosciences, trading at $20.25, has a market cap of $614.2 million and a forward P/E ratio of -21.77.
- Analysts have maintained a 'buy' rating with price targets ranging from $40 to $52.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, Inc., sold 8,587 shares of the company in a planned transaction on June 16, 2026. The shares were sold at an average price of $20.71, amounting to a total value of about $177,837.
Insider Buying and Selling at Castle Biosciences, Inc.
In addition to Kristen Oelschlager's sale, Castle Biosciences has seen several insider transactions recently. Derek Maetzold, President and CEO, bought 550 shares at $2.39 on June 15, 2026, and sold 4,172 shares at $20.66 on the same day in planned transactions. Earlier, on June 1, 2026, Maetzold purchased another 6,214 shares at no cost.
Other Institutional Activity in Castle Biosciences
Institutional investors have also been active in Castle Biosciences. BlackRock, Inc. reduced its holdings by 122,300 shares, ending with 2,982,946 shares valued at about $73.2 million. RTW Investments, LP increased its position by 643,098 shares, totaling 2,758,335 shares worth approximately $67.7 million. Meanwhile, Principal Financial Group Inc cut its stake by 37,767 shares, holding 1,769,877 shares valued at $43.5 million. Portolan Capital Management, LLC decreased its holdings by 379,180 shares, leaving them with 1,350,283 shares valued at $33.1 million. Vanguard Capital Management LLC added 1,177,522 shares, reaching a total of 1,177,522 shares valued at $28.9 million.
Castle Biosciences, Inc. Stock Down 39.6%
Shares of Castle Biosciences, trading on the NasdaqGM under the ticker CSTL, were priced at $20.25. The company has a market capitalization of $614.2 million and a forward P/E ratio of -21.77, indicating it is not currently profitable. The stock has a 52-week range between $14.59 and $44.28, with a 50-day moving average of $22.01 and a 200-day moving average of $28.72. The company's beta is 1.023, suggesting moderate volatility.
$CSTL stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Castle Biosciences reported revenue of $339.9 million, but it experienced a revenue decrease of 4.9%. The company posted a net margin of -3.78% and a return on equity of -2.85%, reflecting challenges in profitability. The next earnings report is expected on August 3, 2026.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Castle Biosciences. On May 13, 2026, BTIG maintained its 'buy' rating with a $40 price target. Baird also reaffirmed its 'buy' rating on May 7, 2026, with a target of $43. Canaccord Genuity echoed this sentiment on April 20, 2026, with a $40 target. The consensus target price among analysts is $44, based on 8 opinions.
About Castle Biosciences
Castle Biosciences, Inc. is a healthcare company specializing in molecular diagnostics to support the diagnosis and treatment of various cancers, including dermatologic cancers and uveal melanoma. Headquartered in Friendswood, Texas, the company is led by CEO Derek J. Maetzold and employs 942 people. Castle Biosciences offers a range of diagnostic tests, such as DecisionDx-Melanoma and TissueCypher, serving the dermatology and gastroenterology markets.
Bottom Line
Kristen Oelschlager's planned sale of shares is part of the regular insider trading activity at Castle Biosciences. The company continues to see significant institutional interest, with both reductions and additions to holdings by major funds. Despite recent financial challenges, analysts remain optimistic, maintaining 'buy' ratings and setting price targets that suggest potential upside. Investors will be watching the upcoming earnings report for further insights into the company's performance.
Get Castle Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CSTL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.